iCo Therapeutics (ICO) Stock Price, News & Analysis

Company Overview

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: C$0.10 to C$0.11
• 50-Day Range: C$0.11 to C$0.11
• 52-Week Range: C$0.02 to C$0.16
• Volume: 1.31 million shs
• Average Volume: 3.16 million shs
• Market Capitalization: C$951,825.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ICO Stock Analysis - Frequently Asked Questions

How have ICO shares performed this year?

iCo Therapeutics' stock was trading at C$0.11 at the beginning of 2025. Since then, ICO shares have increased by 0.0% and is now trading at C$0.11.
View the best growth stocks for 2025 here.

How do I buy shares of iCo Therapeutics?

Shares of ICO stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of iCo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iCo Therapeutics investors own include iCo Therapeutics (ICOTF), Theratechnologies (TH), Nemaska Lithium (NMX), NextSource Materials (NEXT), Meta Platforms (META), Freeport-McMoRan (FCX) and Eldorado Gold (EGO).

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:ICO
• CIK: N/A
• Web: www.icotherapeutics.com
• Phone: +1-604-6029414
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 1.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.01 per share
• Price / Cash Flow: 8.75
• Book Value: C$0.00 per share
• Price / Book: 105.00

Miscellaneous

• Outstanding Shares: 9,065,000
• Free Float: N/A
• Market Cap: C$951,825.00
• Optionable: Not Optionable
• Beta: N/A